Re: Benedikt Hoeh, Felix Preisser, Fabio Zattoni, et al. Risk of Biochemical Recurrence and Metastasis in Prostate Cancer Patients Treated with Radical Prostatectomy After a 10-year Disease-free Interval. Eur Urol Oncol 2025;8:372-9 [0.03%]
Hoeh B, Preisser F, Zattoni F等。根治性前列腺切除术后10年无病间期的前列腺癌生化复发和转移风险。Eur Urol Oncol 2025;8:372-9
Francesco Montorsi,Leonardo Quarta,Alberto Briganti et al.
Francesco Montorsi et al.
FGFR1/3 Signaling as an Achilles' Heel of Phenotypic Diversity in Urothelial Carcinoma [0.03%]
FGFR1/3信号作为表型多样性的薄弱环节在尿路上皮癌中的作用
Renate Pichler,Nils C H van Creij,Laura S Mertens et al.
Renate Pichler et al.
FGFR inhibitors are a new therapeutic option for urothelial carcinoma (UC) with FGFR2/3 alterations. In this study, we analyzed genetic alterations, co-regulation, and differential expression for 45 genes encoding FGF, FGFR, or FGF-binding ...
Fast Biparametric Versus Multiparametric Magnetic Resonance Imaging for Triage of Men with Elevated Prostate-specific Antigen: The PRO-TRIAGE Prospective Comparative Trial [0.03%]
快速双参数与多参数磁共振成像区分前列腺特异性抗原升高男性的筛选价值：PRO-TRIAGE前瞻性比较试验
Hyungwoo Ahn,Mi Yeon Park,Jeong In Shin et al.
Hyungwoo Ahn et al.
Background and objective: The increasing demand for prostate magnetic resonance imaging (MRI) underscores the need for better accessibility. We conducted a prospective study to compare fast biparametric MRI (fast-bpMRI) w...
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer [0.03%]
KEYLYNK-010研究中患者报告结局：派姆单抗联合奥拉帕利对比阿比特龙或恩杂鲁玛用于生物标志物未选择的经治转移去势抵抗性前列腺癌患者的疗效
Niven Mehra,Emmanuel S Antonarakis,Se Hoon Park et al.
Niven Mehra et al.
Background and objective: Pembrolizumab plus olaparib did not significantly improve radiographic progression-free survival or overall survival versus a next-generation hormonal agent (NHA) in participants with biomarker-u...
Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer [0.03%]
高危前列腺癌放射治疗与手术治疗策略的比较研究
Soumyajit Roy,Yilun Sun,James A Eastham et al.
Soumyajit Roy et al.
Background and objective: Optimal management for high-risk prostate cancer is unclear. Using individual patient data from two contemporaneous North American cooperative group phase 3 randomized controlled trials (RCTs), w...
Transcriptomic Analysis of Localized High-risk Prostate Cancer Improves Prognostication and Identifies Benefit from Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase 3 Trial [0.03%]
转录组学分析可改善局部高危前列腺癌的风险分层，并确定在NRG肿瘤学/RTOG 0521三期试验中将多西他赛添加到雄激素抑制联合根治放疗中有益
Ryan M Phillips,James A Proudfoot,Elai Davicioni et al.
Ryan M Phillips et al.
Background and objective: NRG/RTOG 0521 randomized men with high-risk localized prostate cancer (PC) to androgen suppression (AS) and definitive radiotherapy (RT) ± docetaxel-based chemotherapy (CT). The overall survival...
Fabian Falkenbach,Quynh Chi Le,Mattia Longoni et al.
Fabian Falkenbach et al.
Background and objective: Prostate cancer (PCa) is the second most common cancer-specific cause of death in the USA. However, the effects of metastatic or locally advanced PCa on individual years of life lost (YLL) have n...
Assessing the Impact of Treatment Timing Protocols in Clinical Trials for Bacillus Calmette-Guérin-unresponsive Non-muscle-invasive Bladder Cancer [0.03%]
评估卡介菌失败的非肌层浸润性膀胱癌临床试验治疗时间方案的影响
Christopher Guske,Seyed Behzad Jazayeri,Christian Harrs et al.
Christopher Guske et al.
Patients with bacillus Calmette-Guérin (BCG)-unresponsive (UR) non-muscle-invasive bladder cancer (NMIBC) who are ineligible for or decline radical cystectomy may pursue bladder-sparing therapy (BST). Currently, most BST trials in the BCG-...
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis [0.03%]
伴有淋巴结转移的前列腺癌患者新辅助内分泌治疗联合阿昔替尼的II期随机试验
Amado J Zurita,Rebecca S Tidwell,Brian F Chapin et al.
Amado J Zurita et al.
Background and objective: Strategies that combine systemic and locoregional therapies are increasingly used in prostate cancer (PC) with lymph node metastasis (LNM) at presentation. We investigated whether the presurgical...
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer [0.03%]
DNA错配修复缺陷型转移性去势抵抗性前列腺癌患者中抗PD-(L)1免疫治疗的有效性
Sandra van Wilpe,Tarek Taha,Emily C Rothmann et al.
Sandra van Wilpe et al.
Background and objective: Up to 5% of patients with metastatic castration-resistant prostate cancer (mCRPC) harbour loss-of-function alterations in mismatch repair genes (dMMR) resulting in microsatellite instability (MSI...